Washington Trust Bank’s United Therapeutics UTHR Stock Holding History

Washington Trust Bank’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-54	Closed	-$6K	–	745
2018 Q1	$6K	Buy	+54	New	+$6.86K	﹤0.01%	661
2017 Q1	–	Sell	-6	Closed	-$1K	–	960
2016 Q4	$1K	Hold	6	–	–	﹤0.01%	914
2016 Q3	$1K	Buy	+6	New	+$721	﹤0.01%	979

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Washington Trust Bank's UTHR Position: Q2 2018 in Review

Washington Trust Bank sold out of United Therapeutics (UTHR) in Q2 2018, closing a stake of 54 shares — an estimated $6K sold.

Washington Trust Bank first reported a position in UTHR in Q3 2016 and held it in 3 quarters. The position peaked at $6K in Q1 2018. 374 funds tracked by Wall St. Rank hold UTHR as of Q2 2018.

Washington Trust Bank reported no remaining United Therapeutics position as of Q2 2018 after selling out during the quarter.
Washington Trust Bank sold 54 United Therapeutics shares in Q2 2018, an estimated $6K.
Washington Trust Bank first reported a position in United Therapeutics in Q3 2016 and held it in 3 quarters.
Washington Trust Bank's United Therapeutics position peaked at $6K in Q1 2018.
374 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2018.

Based on Washington Trust Bank's 13F filing for Q2 2018, filed 3 Jul 2018.